<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749045</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15090404</org_study_id>
    <nct_id>NCT02749045</nct_id>
  </id_info>
  <brief_title>Simultaneous Assessment of FFR and SPECT</brief_title>
  <official_title>The Simultaneous Assessment of Invasive Fractional Flow Reserve and SPECT Myocardial Ischemia Using Regadenoson in the Catheterization Laboratory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this research study is to identify the disparity in ischemia&#xD;
      measurement between fractional flow reserve (FFR) used in the cardiac catheterization&#xD;
      laboratory and myocardial perfusion stress- single-photon emission computed tomography&#xD;
      (SPECT). This study aims to determine the correlation between simultaneous FFR and SPECT&#xD;
      obtained using regadenoson in the catheterization laboratory.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are previously scheduled for diagnostic coronary angiography will be approached&#xD;
      for consent to be part of the study. If the patient is found to have one or two vessel&#xD;
      disease and it is planned by the interventional cardiologist that FFR will be used, then the&#xD;
      previously consented patient will be deemed appropriate for the study. The standard procedure&#xD;
      will be followed for FFR testing using regadenoson. The patient will then receive the&#xD;
      standard dose of Tc-99m sestamibi. The interventional cardiologist will proceed with&#xD;
      percutaneous coronary intervention (PCI) if appropriate. Patients will proceed to the cardiac&#xD;
      catheterization laboratory holding area post procedure. Patients will then be scheduled to be&#xD;
      taken to the nuclear cardiology laboratory one to three hours following the coronary&#xD;
      angiogram for standard SPECT acquisition. Patients will be monitored for 2-6 hours or&#xD;
      overnight as clinically indicated following diagnostic coronary angiography and PCI. Low dose&#xD;
      resting myocardial perfusion scanning may be performed the next day if stress myocardial&#xD;
      perfusion study was abnormal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative perfusion defect analysis using Quantitative Gated SPECT (Cedars-Sinai Medical Center) to determine the total perfusion defect size</measure>
    <time_frame>Within 4 hr post radiotracer injection (based on 6 hr half-life of radiotracer)</time_frame>
    <description>Concordance between gated SPECT perfusion data (QGS) and fractional flow reserve (FFR)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Image acquisition arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects who have undergone a clinically indicated fractional flow reserve measurement in the cardiac catheterization laboratory will receive standard dose Tc-99m sestamibi and undergo resting SPECT image acquisition within three hours from end of cardiac catheterization procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SPECT imaging</intervention_name>
    <description>myocardial perfusion imaging</description>
    <arm_group_label>Image acquisition arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients undergoing clinically-indicated FFR measurement (to determine the hemodynamic&#xD;
        significance of intermediate degrees of stenosis) for single or two -vessel epicardial&#xD;
        coronary disease during diagnostic coronary angiography for suspected coronary artery&#xD;
        disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with 3-vessel disease&#xD;
&#xD;
          2. Prior coronary artery bypass grafting&#xD;
&#xD;
          3. Patients with second or third- degree atrioventricular block, without a functioning&#xD;
             pacemaker&#xD;
&#xD;
          4. Patients who have ingested caffeine-containing products within the past 12 hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prem Soman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Prem Soman</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

